Byongen Therapeutics

Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance to develop next-generation gene therapies for Duchenne muscular dystrophy (DMD). Collaboration FocusGene Cradle, which initiated its DMD gene therapy project in 2021, has focused on optimizing Dystrophin proteins and regulatory elements. The company has designed…